Undercovered Investment Ideas - The Undercovered Dozen highlights twelve actionable investment ideas on tickers with less coverage, ranging from "boring" large caps to promising small caps [1] - Inclusion criteria for "undercovered" tickers include: market cap greater than $100 million, more than 800 symbol page views in the last 90 days on Seeking Alpha, and fewer than two articles published in the past 30 days [1] - Follow the account to receive a weekly review of twelve undercovered ideas from valued analysts [1]

Technical Analysis - Natera (NTRA) has surpassed resistance at the 20-day moving average, indicating a short-term bullish trend [1] - The stock has rallied 11.3% over the past four weeks, with a current price of $166.55 and a 20-day simple moving average of $167.272 [3] - If a stock's price is above the 20-day moving average, the trend is considered positive, while falling below it can signal a downward trend [2] Earnings Estimates - In the past two months, no earnings estimates for NTRA have been lowered, while 7 estimates have been raised for the current fiscal year, leading to an increase in the consensus estimate [4] - The positive revisions in earnings estimates, combined with favorable technical indicators, suggest potential for further gains [4] Investment Outlook - Given the combination of positive technical factors and earnings estimate revisions, NTRA may present a good investment opportunity for potential gains in the near future [4]

Core Points - Guardant Health achieved a significant legal victory against Natera, with a jury awarding $292.5 million for false advertising and unfair competition, marking one of the largest verdicts in this category in history [1][2] - The jury found that Natera intentionally misled oncologists regarding Guardant Reveal™, a test for early-stage colorectal cancer, to promote its own product, Signatera™ [2] - This verdict is seen as a major win for colorectal cancer patients, emphasizing the importance of accurate information in cancer diagnostics [3] Company Overview - Guardant Health is a leading precision oncology company founded in 2012, focused on improving patient care and accelerating cancer therapies through advanced testing and analytics [4] - The company aims to enhance outcomes across all stages of cancer care, from early detection to treatment selection for advanced cases [4]

Core Insights - Natera reported a revenue of $439.76 million for the quarter ended September 2024, marking a 63.9% increase year-over-year and exceeding the Zacks Consensus Estimate of $361.16 million by 21.76% [1] - The company's EPS was -$0.26, an improvement from -$0.95 in the same quarter last year, with a surprise of 54.39% compared to the consensus estimate of -$0.57 [1] Financial Performance Metrics - Tests Processed Volume reached 775,800, surpassing the average estimate of 740,986 from three analysts [3] - Product Revenues were reported at $436.13 million, exceeding the estimated $357.01 million by four analysts, reflecting a year-over-year increase of 64.4% [3] - Revenues from Licensing and other sources amounted to $3.63 million, compared to the average estimate of $2.94 million, representing a 17.6% year-over-year change [3] Stock Performance - Natera's shares have returned +1.6% over the past month, while the Zacks S&P 500 composite increased by +3.3% [4] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance against the broader market in the near term [4]

Natera (NTRA) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.57. This compares to loss of $0.95 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 54.39%. A quarter ago, it was expected that this genetic testing company would post a loss of $0.69 per share when it actually produced a loss of $0.30, delivering a surprise of 56.52%.Over the last four quarters, the company has s ...

Wall Street expects a year-over-year increase in earnings on higher revenues when Natera (NTRA) reports results for the quarter ended June 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates. The earnings report might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may mo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 NATERA, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 01-0894487 (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 13011 McCallen Pass Building A Suite 100 Austin, TX 78753 (Address of Principal Executive Offices) (Zip Code) (650) 980-919 ...

Natera (NTRA) reported $367.74 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 52.1%. EPS of -$0.56 for the same period compares to -$1.23 a year ago.The reported revenue represents a surprise of +18.04% over the Zacks Consensus Estimate of $311.54 million. With the consensus EPS estimate being -$0.72, the EPS surprise was +22.22%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Str ...

Exhibit 99.1 Natera Reports First Quarter 2024 Financial Results AUSTIN, Texas, May 9, 2024 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. "We had an excellent start to the year, driving robust volume, revenue and margin growth and achieving cash flow breakeven earlier than expected," said Steve Chapman, chief executive officer of Natera. "We continued to deliver on our mission ...

Since inception, Natera (NASDAQ:NTRA) has incurred sustained losses, with their cash burn rate being one of the largest concerns to investors. However, the company seems to be on the verge of becoming profitable for the first time in its history. In my opinion, this is mostly due to the growth of the personalised medicines, particularly in oncology, together with the recently approved biomarkers law in 13 U.S. states. Thus, I consider that Natera as a “buy,” despite the risks associated with it. Personalise ...